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Reviews and Overviews
cant and large effects for IPT compared with placebo or no 
treatment, and superior effects of IPT compared with CBT. 
A substantial number of studies of IPT have been pub-
lished since then. Furthermore, the earlier meta-analysis 
did not examine heterogeneity, possible effect moderators 
that may explain heterogeneity, publication bias, or the 
quality of included studies. We therefore decided to con-
duct a new meta-analysis to examine whether IPT is an 
efficacious treatment and deserves the prominent place it 
currently holds in treatment guidelines.
Method
Search Strategy
We searched the literature using several methods. First, we 
used our existing database on psychological treatment of de-
pression in adults, which is continuously updated and currently 
contains 1,122 full-text papers. This database, described in detail 
elsewhere (22), has been used in a series of earlier meta-analyses 
(www.evidencebasedpsychotherapies.org). We also conducted a 
comprehensive literature search (from 1966 to January 2010) in 
PubMed, PsycINFO, EMBASE, the Cochrane Central Register of 
(Am J Psychiatry Cuijpers et al.; AiA:1–12)
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Objective: Interpersonal psychotherapy 
(IPT), a structured and time-limited ther-
apy, has been studied in many controlled 
trials. Numerous practice guidelines have 
recommended IPT as a treatment of 
choice for unipolar depressive disorders. 
The authors conducted a meta-analysis 
to integrate research on the effects of IPT.
Method: The authors searched biblio-
graphical databases for randomized con-
trolled trials comparing IPT with no treat-
ment, usual care, other psychological 
treatments, and pharmacotherapy as well 
as studies comparing combination treat-
ment using pharmacotherapy and IPT. 
Maintenance studies were also included.
Results: Thirty-eight studies including 
4,356 patients met all inclusion criteria. 
The overall effect size (Cohen’s d) of the 
16 studies that compared IPT and a con-
trol group was 0.63 (95%  confidence inter-
val [CI]=0.36 to 0.90), corresponding to a 
number needed to treat of 2.91. Ten stud-
ies comparing IPT and other psychological 
treatments showed a nonsignificant dif-
ferential effect size of 0.04 (95%  CI=–0.14 
to 0.21; number needed to treat=45.45) 
favoring IPT. Pharmacotherapy (after re-
moval of one outlier) was more effective 
than IPT (d=–0.19, 95%  CI=–0.38 to –0.01; 
number needed to treat=9.43), and com-
bination treatment was not more effec-
tive than IPT alone, although the paucity 
of studies precluded drawing definite 
conclusions. Combination maintenance 
treatment with pharmacotherapy and 
IPT was more effective in preventing re-
lapse than pharmacotherapy alone (odds 
ratio=0.37; 95%  CI=0.19 to 0.73; number 
needed to treat=7.63).
Conclusions: There is no doubt that IPT 
efficaciously treats depression, both as an 
independent treatment and in combina-
tion with pharmacotherapy. IPT deserves 
its place in treatment guidelines as one of 
the most empirically validated treatments 
for depression.
Unipolar depressive disorders have a high preva-
lence (1, 2) and incidence (3), and they meaningfully im-
pair quality of life for patients and their relatives (4, 5). 
Moreover, depressive disorders are linked with increased 
mortality rates (6), high levels of health service use, and 
huge economic costs (7–9). Major depression ranks fourth 
in disease burden worldwide, and it is expected to rank 
first in high-income countries by 2030 (10).
Practice guidelines recommend both pharmacological 
and psychological interventions for depressive disorders 
(11–14). Interpersonal psychotherapy (IPT) is recom-
mended in these guidelines as one of the two psycho-
logical treatments of choice, the other being cognitive-be-
havioral therapy (CBT). IPT is a structured, time-limited 
psychological intervention based on interpersonal theory 
(15–18) and specifically developed for the treatment of 
major depression (19, 20).
Although numerous randomized controlled trials have 
examined the effects of IPT, only one meta-analysis has 
been conducted to evaluate IPT for depression (21). That 
analysis included a total of 13 studies and found signifi-
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formulas Kraemer and Kupfer provide (32). The number needed 
to treat indicates the number of patients who must receive treat-
ment to generate an additional positive outcome in the experi-
mental group relative to the comparison group (33).
For the IPT maintenance studies, we calculated the odds ratio 
of recurrence of depression in maintenance IPT compared with a 
control condition, as well as the number needed to treat (in this 
case as the reverse of the risk difference).
We also performed subgroup analyses to test for significant 
differences between effect sizes in different categories of stud-
ies. In these analyses, we used the mixed-effects model, which 
pooled studies within subgroups with the random-effects model 
but tested for significant differences between subgroups with the 
fixed-effects model. If a subgroup contained fewer than three 
studies, we did not conduct the subgroup analysis. Because there 
are indications that psychological treatments of dysthymia are 
less effective (33), we decided to repeat all analyses after remov-
ing studies specifically targeting patients with dysthymia.
Publication bias was examined by inspecting the funnel plot. 
A funnel plot is a plot of a measure of study size (the standard er-
ror) on the vertical axis as a function of effect size on the horizon-
tal axis. Large studies appear at the top of the graph and tend to 
cluster near the mean effect size. Smaller studies appear toward 
the bottom of the graph. As there is greater sampling variation 
in effect size estimates in the smaller studies, they will be dis-
persed across a range of values (34). Visual inspection of a funnel 
plot can give an indication of publication bias. The studies can 
be expected to spread symmetrically about the pooled effect size 
when publication bias is absent. When bias exists, the bottom 
of the plot will show a higher concentration of studies on one 
side of the mean than the other. This is because smaller studies 
are more likely to be published if they have larger than average 
effects, which makes them more likely to meet the criterion for 
statistical significance.
We also examined possible publication bias using Duval and 
Tweedie’s trim-and-fill procedure (34). If a meta-analysis has in-
cluded all relevant studies, the funnel plot should be symmetric 
and dispersed equally on either side of the mean effect. If there is 
publication bias, the funnel plot will be asymmetric, with more 
studies to the right side of the mean effect size (studies with large 
effect sizes) than to the left of the mean (studies with small or 
nonsignificant effect sizes, which can be expected to be harder 
to publish). Duval and Tweedie developed a method for imput-
ing missing studies based on the assumption that studies should 
be equally distributed on both sides of the mean effect size. This 
procedure yields an estimate of the effect size after accounting for 
publication bias (adjusted effect size).
Power Calculation
We expected that several comparisons (e.g., IPT compared with 
pharmacotherapy, or pharmacotherapy compared with combi-
nation treatment) would involve only a limited number of stud-
ies. We therefore conducted a power calculation to assess wheth-
er the included studies had sufficient statistical power to detect 
small effect sizes. Although there are no clear definitions for what 
constitutes a small effect size, we defined a small effect as d=0.2, 
according to the indications of Cohen (30), but we also examined 
how many studies would be needed to find an effect size of 0.3.
We conducted the power calculation according to the proce-
dures described by Borenstein and colleagues (35). A power cal-
culation indicated that we would need to include at least 32 stud-
ies with a mean sample size of 50 (25 participants per condition) 
to be able to detect an effect size of 0.2 (conservatively assuming 
a high level of between-study variance [τ2], a statistical power of 
0.80, and an alpha of 0.05). Alternatively, we would need 20 stud-
ies with 80 participants apiece to detect an effect size of 0.2, or 16 
studies with 100 participants. To detect an effect size of 0.3, we 
Controlled Trials, and Dissertation Abstracts International. We 
identified abstracts by combining terms indicative of psycho-
logical treatment and depression. We also collected the primary 
studies from 42 meta-analyses of psychological treatment for de-
pression. Second, we carried out an additional literature search 
(from 1966 to January 2010) in PubMed, PsycINFO, and EMBASE 
to retrieve studies of IPT in adolescents. Third, we collected the 
primary studies from the previous meta-analysis of IPT (21) and 
checked the reference lists of included studies.
Inclusion and Exclusion Criteria
We included studies of randomized controlled trials in which 
IPT for adults or adolescents with a unipolar depressive disor-
der or an elevated level of depressive symptoms was compared 
with waiting list, usual care, placebo, psychological treatment, 
pharmacological treatment, or combination treatment with IPT 
and pharmacotherapy. We also included maintenance studies in 
which patients were successfully treated during the acute treat-
ment phase and then randomized to receive IPT or another treat-
ment condition in the continuation phase.
We excluded studies that examined interpersonal counseling 
for subthreshold depression (23–26) because interpersonal coun-
seling differs considerably from full IPT and is not intended for 
individuals with full-syndrome depressive disorders. No language 
restrictions were applied. Eligibility judgment was performed in-
dependently by two reviewers (A.S.G. and P.C.). In case of incon-
sistency, a third reviewer (A.v.S.) was consulted.
Quality Assessment
We assessed the validity of the studies according to the basic cri-
teria suggested by the Cochrane Handbook for Systematic Reviews 
of Interventions (27): adequate sequence generation (the random-
ization scheme was generated correctly); allocation to conditions 
by an independent (third) party; blinding of assessors of outcomes; 
completeness of follow-up data; and no selective outcome report-
ing. (We omitted the criterion of adequacy of random allocation 
concealment to respondents because concealment of random al-
location is impossible in psychological treatment.)
Analyses
We calculated effect sizes (Cohen’s d) for all individual studies 









 is the mean of the outcome measures in the con-
trol group, M
e
 is the mean of the outcome measures in the experi-
mental groups, and SD
ec
 is the pooled standard deviation of the 
posttest scores of the two groups (28, 29). An effect size of 0.8 can 
be considered large, 0.5 moderate, and 0.2 small (30). For studies 
that reported more than one outcome, a single pooled effect size 
was calculated for each study.
The individual effect sizes were pooled in the Comprehensive 
Meta-Analysis (CMA) software program (www.meta-analysis.
com). Pooled effect sizes were calculated separately for posttest 
comparisons of IPT with usual care, no treatment, or placebo; 
with other psychotherapy; and with pharmacotherapy; in addi-
tion, combination treatment with IPT and pharmacotherapy was 
compared with pharmacotherapy alone.
Because we expected considerable heterogeneity, we calculat-
ed pooled effect sizes with the random-effects model. However, 
we first tested the heterogeneity under the fixed model using the 
I2 statistic (31). I2 describes the variance between studies as a pro-
portion of the total variance. A value of 25% indicates low hetero-
geneity, 50% moderate heterogeneity, and 75% high heterogene-
ity. We also report the p value of the Q statistic. A significant Q 
value rejects the null hypothesis of homogeneity.
The standardized mean difference is not easy to interpret from 
a clinical viewpoint. Therefore, we transformed the standardized 
mean differences into the numbers needed to treat, using the 
cuIjPers, GerAeDts, vAn oPPen, et Al.
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19 did not report a sequence generation method. Twelve 
studies reported allocation to conditions by an indepen-
dent (third) party. Twenty-five studies reported using 
blinded outcome assessors, 10 did not report blinding of 
assessors, and three used self-report outcome measures. 
In 28 studies intent-to-treat analyses (completeness of 
follow-up data) were conducted. Nine studies (24%) met 
all quality criteria.
IPT Compared With Standard or No Treatment
We were able to compare the effects of IPT with a waiting 
list, usual care, or placebo control condition in 16 studies 
(Table 2). The mean effect size (Cohen’s d) was 0.63 (95% 
confidence interval [CI]=0.36 to 0.90), which corresponds 
to a number needed to treat of 2.91. Heterogeneity was 
high (I2=82.96%). After removal of a possible outlier, the 
mean effect size decreased to 0.52 (95% CI=0.36 to 0.68; 
number needed to treat=3.50), with low to moderate het-
erogeneity (I2=42.84%). Meta-analyses based on the two 
most commonly used instruments (the 17-item Hamil-
ton Depression Rating Scale [HAM-D] and the Beck De-
pression Inventory [BDI]) yielded comparable outcomes 
(Table 2). Figure 2 presents the effect sizes and confidence 
intervals.
The 16 studies had on average 92 participants (46 in the 
IPT and 46 in the control conditions). This generated suffi-
would need 14 studies with 50 participants, nine studies with 80 
participants, or seven studies with 100 participants.
results
Selection and Inclusion of  Studies
Having examined a total of 10,487 abstracts, we re-
trieved 1,209 full-text papers for further study. Of these, we 
excluded 1,171 papers that did not meet inclusion criteria 
(Figure 1). A total of 38 studies met all inclusion criteria 
and were included in this meta-analysis (36–73).
Characteristics of  Included Studies
The 38 studies included 4,356 patients (1,338 in the IPT 
conditions, 812 in control conditions, 713 in pharmaco-
therapy conditions, 468 in other psychotherapy condi-
tions, 510 in combination treatment with IPT and phar-
macotherapy, and 515 in maintenance studies). Selected 
characteristics of the included studies are presented in 
Table 1.
Thirty-three of the 38 studies examined the effects of IPT 
as an acute treatment, and the remaining five examined 
IPT as a maintenance treatment after successful recovery 
from a depressive disorder. Sixteen studies compared IPT 
with a control condition (waiting list, usual care, placebo, 
other), 10 compared IPT with another psychotherapy, 10 
contrasted IPT with pharmacotherapy, and 10 compared a 
combination treatment (IPT plus pharmacotherapy) with 
pharmacotherapy alone. Of the 16 studies comparing IPT 
with a control condition, eight used usual care as the con-
trol condition, three used a waiting list control group, two 
used a pill placebo, and three used another control group 
(monthly 30-minute nontherapeutic sessions; a parent-
ing education control program; and nonscheduled treat-
ment).
In 29 studies patients met criteria for a depressive dis-
order according to a diagnostic interview (four studies 
specifically targeted dysthymic patients); in four studies, 
patients had scored above a cutoff on a depression ques-
tionnaire. Seventeen studies treated adults in general, six 
treated adolescents, four treated older adults, four treated 
patients with somatic disorders, two treated women with 
postpartum depression, and the remaining five treated 
other, more specific target groups. Fourteen studies used 
the original IPT manual, and 19 reported having adapted 
the manual to the needs of the study’s target population. 
Adaptations were minor and included adapting the num-
ber of sessions, addressing specific needs of the target 
groups, and changing the individual format to a group for-
mat. The 38 studies were conducted in 13 countries, with 
most in the United States (N=21, including two in Puerto 
Rico) and Europe (N=7).
Quality Assessment
The quality of the studies varied. Nineteen studies re-
ported an adequate sequence generation, while the other 
fIGure 1. flow chart of the selection of studies of Inter-







 Additional search on  
 adolescents (N=141) 
  PubMed (N=49)
  PsycINFO (N=78)
  Embase (N=14)
Studies excluded by 
abstract and title 
(N=9,278)





 Duplicate publication (N=274)
 No random assignment (N=58)
 Not only depression (N=135)
 No psychotherapy (N=155)
 No control condition (N=105)
 No IPT (N=283)
 Other reasons (N=161)
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tABle 1. selected characteristics of 38 randomized controlled trials of Interpersonal Psychotherapy in Patients 
With Depressive Disorders
Study Authors  
(Reference Number)
IPT  
Typea Diagnosis (Basis of Diagnosis)b Target Group Study Interventionsc (N) Formatd
Sessions  
(N) ITTe Outcome Measuresb Countryf
Bellino et al. (36) O Major depression (clinical judgment) Adults with borderline personality disorder IPT+PHA (N=20); PHA (N=19) IND 24 N HAM-D IT
Blom et al. (37) O Major depression (SCID) and HAM-D ≥14 Adult outpatients IPT (N=50); IPT+PHA (N=49); PHA (N=47); IPT+PLA (N=47) IND 12 Y HAM-D, MADRS NL
Bodenmann et al. (38) O Major depression or dysthymia (SCID) Adults over age 60 (and their partners) IPT (N=20); COCT (N=20); CBT (N=20) IND 20 Y HAM-D, BDI SW
Bolton et al. (39) A
Major depression or subsyndromal depression (clinical 
interview) Adults IPT (N=107); UC (N=117) GRP 16 Y
Specially developed measures for 
local use UG
Bolton et al. (40) A
Major depression or subsyndromal depression (clinical 
interview)
Adolescent survivors of war and displace-
ment IPT (N=105); WL (N=104); creative play (N=105) GRP 16 Y
Specially developed measures for 
local use UG
Browne et al. (41) O Dysthymia (SCID) with or without major depression Adults IPT (N=178); IPT+PHA (N=212); PHA (N=196) IND 10 N MADRS CA
De Mello et al. (42) A
Dysthymia (clinical interview), major depression 
permitted Adults IPT+PHA (N=16); PHA (N=19) IND 16 N HAM-D, MADRS BR
Elkin et al. (43) O Major depression (RDC) and HAM-D ≥14 Adults IPT (N=61); CBT (N=59); PHA (N=57); PLA (N=62) IND 16 Y HAM-D, BDI US
Finkenzeller et al. (44) A HAM-D ≥14 Stroke patients IPT (N=27); IPT+PHA (N=23); PHA (N=24) GRP 8 Y HAM-D, HADS GE
Frank et al. (45) M
Recovered from major depression (RDC) after acute 
treatment (PHA+weekly IPT)c Adults
M-IPT+M-PHA (N=25); M-PHA (N=28); M-IPT (N=26);  
M-IPT+PLA (N=26); PLA (N=23) IND Monthly Y Recurrence rate after 3 years US
Lespérance et al. (46) O Major depression (SCID) and HAM-D-24 ≥20 Patients with coronary artery disease IPT+PHA (N=67); PHA (N=75); IPT+PLA (N=75); PLA (N=67) IND 12 Y HAM-D CA
Klerman et al. (47) M
Clinical improvement after acute treatment (PHAc) for 
neurotic depression (DSM-II) Adults
M-IPT+M-PHA (N=25); M-IPT+PLA (N=25); M-IPT (N=25); 
M-PHA (N=25); PLA (N=25); clinical management only 
(N=25) IND Weekly Y Recurrence rate after 8 months US
Levkovitz et al. (48) M
Recovered from major depression (DSM-IV) after acute 
treatment (PHAc) Adults M-IPT+M-PHA (N=7); M-PHA (N=7) GRP 18 Y HAM-D score at 6-month follow-up IS
Luty et al. (49) O Major depression (SCID; DSM-III-R) Adults IPT (N=91); CBT (N=86) IND 16 Y MADRS NZ
Markowitz et al. (50) A
HAM-D-24 ≥15 and clinical judgment of depressive 
symptoms HIV patients IPT (N=24); SUP (N=24); CBT (N=27); SUP+PHA (N=26) IND 11 Y BDI, HAM-D US
Markowitz et al. (51) A Dysthymia (SCID) and HAM-D-24 >13 Adults IPT (N=23); IPT+PHA (N=21); SUP (N=26); PHA (N=24) IND 16 Y BDI, CDRS, HAM-D US
Markowitz et al. (52) A Dysthymia (SCID) and HAM-D-24 >13 Adults with secondary alcohol use disorder IPT (N=14); SUP (N=12) IND 16 Y BDI, CDRS, HAM-D US
Marshall et al. (53) O Major depression (SCID) and HAM-D ≥10 Adults IPT (N=35); CBT (N=37); PHA (N=30) IND 16 N HAM-D CA
Martin et al. (54) O Major depression (clinical judgment) and HAM-D ≥18 Adults IPT (N=13); PHA (N=15) IND 16 Y BDI, HAM-D UK
Mufson et al. (55) A HAM-D-24 ≥15 Adolescents IPT (N=24); monitoring (N=24) IND 12 Y BDI, HAM-D US
Mufson et al. (56) A Mood disorder (K-SADS) Adolescents IPT (N=34); UC (N=29) IND 12 Y BDI, HAM-D US
Mulcahy et al. (57) A Major depression (DSM-IV, MCMI-III) Women with postpartum depression IPT (N=29); UC (N=28) GRP 10 N EPDS, BDI, HAM-D AU
Neimeyer and Feixas (58) O Major depression (RDC) and BDI >15 Adults
IPT (N=39); CBT+homework (N=32); CBT, no homework 
(N=31) GRP 10 N HAM-D US
O’Hara et al. (59) A Major depression (SCID) and HAM-D ≥12 Women with postpartum depression IPT (N=60); WL (N=60) IND 12 Y BDI, HAM-D US
Ransom et al. (60) A Major depression or dysthymia (PRIME-MD) Rural HIV patients IPT (N=41); UC (N=38) TEL 10 Y BDI US
Reynolds et al. (61) A Major depression (SADS, SCID) Bereaved adults (age 50 or older) IPT+PHA (N=16); PHA (N=25) IND 16 Y HAM-D US
Reynolds et al. (62) M
Recovered from major depression after 16-week acute 
treatment (PHA + weekly IPT)c Older adults
M-PHA+M-IPT (N=25); M-PHA (N=28); M-IPT+PLA 
(N=25); PLA (N=29) IND Monthly Y Recurrence rate after 3 years US
Reynolds et al. (63) M
Recovered from major depression after 22-week acute 
treatment (PHA + weekly IPT)c Older adults
M-PHA+M-IPT (N=28); M-PHA (N=35); M-IPT+PLA 
(N=35); PLA (N=18) IND Monthly Y Recurrence rate after 2 years US
Rosselló and Bernal (64) A Major depression and/or dysthymia (DISC) Adolescents IPT (N=23); CBT (N=25); WL (N=23) IND 12 Y CDI PR
Rosselló et al. (65) A Major depression (DISC) or CDI ≥13 Adolescents IPT (N=60); CBT (N=52) IND+ GRP 12 Y CDI PR
Schramm et al. (66) A Major depression (SCID) and HAM-D ≥16 Adult inpatients IPT+PHA (N=63); PHA (N=61) IND+ GRP 23 Y BDI, HAM-D GE
Schulberg et al. (67) O Major depression (DIS) and HAM-D ≥13 Adults IPT (N=93); PHA (N=91); UC (N=92) IND 16 Y HAM-D US
Sloane et al. (68) O Major depression (RDC) and HAM-D ≥17 Older adults IPT (N=19); PHA (N=10); PLA (N=14) IND 6 N BDI, HAM-D US
Spinelli and Endicott (69) A Major depression (SCID) and HAM-D-24 ≥12 Pregnant women IPT (N=21); parenting education (N=17) IND 10 Y BDI, EPDS, HAM-D US
Swartz et al. (70) A Major depression (SCID) and HAM-D ≥15
Mothers whose children receive psychiatric 
treatment IPT (N=26); UC (N=21) IND 9 N BDI, HAM-D US
Tang et al. (71) A BDI >19 Adolescents IPT (N=35); UC (N=38) IND 12 Y BDI TW
Van Schaik et al. (72) O Major depression (PRIME-MD) Older adults (age 55 or older) IPT (N=69); UC (N=74) IND 8 Y GDS, MADRS, PRIME-MD NL
Weissman et al. (73) O Major depression (SADS) and RTADS ≥7 Adults
IPT (N=17); IPT+PHA (N=23); on-demand telephone 
support (N=21); PHA (N=20) IND 16 N RTADS US
a A=acute treatment using an adapted manual; M=maintenance treatment; O=acute treatment using original manual.
b BDI=Beck Depression Inventory; CDI=Children’s Depression Inventory; CDRS=Cornell Dysthymia Rating Scale; CES-D=Center for Epidemio-
logic Studies Depression Scale; DIS=Diagnostic Interview Schedule; DISC=Diagnostic Interview Schedule for Children; EPDS=Edinburgh 
Postnatal Depression Scale; GDS=Geriatric Depession Scale; HADS=Hospital Anxiety and Depression Scale; HAM-D=17-item Hamilton 
Depression Rating Scale; HAM-D-24=24-item Hamilton Depression Rating Scale; K-SADS=Schedule for Affective Disorders and Schizo-
phrenia for School-Age Children; MADRS=Montgomery-Åsberg Depression Rating Scale; MCMI-III=Millon Clinical Multiaxial Inventory-III; 
PRIME-MD=Primary Care Evaluation of Mental Disorders; RDC=Research Diagnostic Criteria; RTADS=Raskin Three Area Depression Scale; 
SADS=Schedule for Affective Disorders and Schizophrenia; SCID=Structured Clinical Interview for DSM-IV Axis I Disorders.
c CBT=cognitive-behavioral therapy; COCT=coping-oriented couples therapy; IPT=interpersonal psychotherapy; PHA=pharmacotherapy; 
PLA=placebo; SUP=supportive psychotherapy; UC=usual care; WL=waiting list.
d GRP=Group treatment; IND=individual treatment; TEL=telephone treatment.
e ITT=intent to treat; N=no; Y=yes.
f AU=Australia; BR=Brazil; CA=Canada; GE=Germany; IS=Israel; IT=Italy; NL=Netherlands; NZ=New Zealand; PR=Puerto Rico; SW=Sweden; 
TW=Taiwan; UG=Uganda; UK=United Kingdom; US=United States.
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IPT  
Typea Diagnosis (Basis of Diagnosis)b Target Group Study Interventionsc (N) Formatd
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(N) ITTe Outcome Measuresb Countryf
Bellino et al. (36) O Major depression (clinical judgment) Adults with borderline personality disorder IPT+PHA (N=20); PHA (N=19) IND 24 N HAM-D IT
Blom et al. (37) O Major depression (SCID) and HAM-D ≥14 Adult outpatients IPT (N=50); IPT+PHA (N=49); PHA (N=47); IPT+PLA (N=47) IND 12 Y HAM-D, MADRS NL
Bodenmann et al. (38) O Major depression or dysthymia (SCID) Adults over age 60 (and their partners) IPT (N=20); COCT (N=20); CBT (N=20) IND 20 Y HAM-D, BDI SW
Bolton et al. (39) A
Major depression or subsyndromal depression (clinical 
interview) Adults IPT (N=107); UC (N=117) GRP 16 Y
Specially developed measures for 
local use UG
Bolton et al. (40) A
Major depression or subsyndromal depression (clinical 
interview)
Adolescent survivors of war and displace-
ment IPT (N=105); WL (N=104); creative play (N=105) GRP 16 Y
Specially developed measures for 
local use UG
Browne et al. (41) O Dysthymia (SCID) with or without major depression Adults IPT (N=178); IPT+PHA (N=212); PHA (N=196) IND 10 N MADRS CA
De Mello et al. (42) A
Dysthymia (clinical interview), major depression 
permitted Adults IPT+PHA (N=16); PHA (N=19) IND 16 N HAM-D, MADRS BR
Elkin et al. (43) O Major depression (RDC) and HAM-D ≥14 Adults IPT (N=61); CBT (N=59); PHA (N=57); PLA (N=62) IND 16 Y HAM-D, BDI US
Finkenzeller et al. (44) A HAM-D ≥14 Stroke patients IPT (N=27); IPT+PHA (N=23); PHA (N=24) GRP 8 Y HAM-D, HADS GE
Frank et al. (45) M
Recovered from major depression (RDC) after acute 
treatment (PHA+weekly IPT)c Adults
M-IPT+M-PHA (N=25); M-PHA (N=28); M-IPT (N=26);  
M-IPT+PLA (N=26); PLA (N=23) IND Monthly Y Recurrence rate after 3 years US
Lespérance et al. (46) O Major depression (SCID) and HAM-D-24 ≥20 Patients with coronary artery disease IPT+PHA (N=67); PHA (N=75); IPT+PLA (N=75); PLA (N=67) IND 12 Y HAM-D CA
Klerman et al. (47) M
Clinical improvement after acute treatment (PHAc) for 
neurotic depression (DSM-II) Adults
M-IPT+M-PHA (N=25); M-IPT+PLA (N=25); M-IPT (N=25); 
M-PHA (N=25); PLA (N=25); clinical management only 
(N=25) IND Weekly Y Recurrence rate after 8 months US
Levkovitz et al. (48) M
Recovered from major depression (DSM-IV) after acute 
treatment (PHAc) Adults M-IPT+M-PHA (N=7); M-PHA (N=7) GRP 18 Y HAM-D score at 6-month follow-up IS
Luty et al. (49) O Major depression (SCID; DSM-III-R) Adults IPT (N=91); CBT (N=86) IND 16 Y MADRS NZ
Markowitz et al. (50) A
HAM-D-24 ≥15 and clinical judgment of depressive 
symptoms HIV patients IPT (N=24); SUP (N=24); CBT (N=27); SUP+PHA (N=26) IND 11 Y BDI, HAM-D US
Markowitz et al. (51) A Dysthymia (SCID) and HAM-D-24 >13 Adults IPT (N=23); IPT+PHA (N=21); SUP (N=26); PHA (N=24) IND 16 Y BDI, CDRS, HAM-D US
Markowitz et al. (52) A Dysthymia (SCID) and HAM-D-24 >13 Adults with secondary alcohol use disorder IPT (N=14); SUP (N=12) IND 16 Y BDI, CDRS, HAM-D US
Marshall et al. (53) O Major depression (SCID) and HAM-D ≥10 Adults IPT (N=35); CBT (N=37); PHA (N=30) IND 16 N HAM-D CA
Martin et al. (54) O Major depression (clinical judgment) and HAM-D ≥18 Adults IPT (N=13); PHA (N=15) IND 16 Y BDI, HAM-D UK
Mufson et al. (55) A HAM-D-24 ≥15 Adolescents IPT (N=24); monitoring (N=24) IND 12 Y BDI, HAM-D US
Mufson et al. (56) A Mood disorder (K-SADS) Adolescents IPT (N=34); UC (N=29) IND 12 Y BDI, HAM-D US
Mulcahy et al. (57) A Major depression (DSM-IV, MCMI-III) Women with postpartum depression IPT (N=29); UC (N=28) GRP 10 N EPDS, BDI, HAM-D AU
Neimeyer and Feixas (58) O Major depression (RDC) and BDI >15 Adults
IPT (N=39); CBT+homework (N=32); CBT, no homework 
(N=31) GRP 10 N HAM-D US
O’Hara et al. (59) A Major depression (SCID) and HAM-D ≥12 Women with postpartum depression IPT (N=60); WL (N=60) IND 12 Y BDI, HAM-D US
Ransom et al. (60) A Major depression or dysthymia (PRIME-MD) Rural HIV patients IPT (N=41); UC (N=38) TEL 10 Y BDI US
Reynolds et al. (61) A Major depression (SADS, SCID) Bereaved adults (age 50 or older) IPT+PHA (N=16); PHA (N=25) IND 16 Y HAM-D US
Reynolds et al. (62) M
Recovered from major depression after 16-week acute 
treatment (PHA + weekly IPT)c Older adults
M-PHA+M-IPT (N=25); M-PHA (N=28); M-IPT+PLA 
(N=25); PLA (N=29) IND Monthly Y Recurrence rate after 3 years US
Reynolds et al. (63) M
Recovered from major depression after 22-week acute 
treatment (PHA + weekly IPT)c Older adults
M-PHA+M-IPT (N=28); M-PHA (N=35); M-IPT+PLA 
(N=35); PLA (N=18) IND Monthly Y Recurrence rate after 2 years US
Rosselló and Bernal (64) A Major depression and/or dysthymia (DISC) Adolescents IPT (N=23); CBT (N=25); WL (N=23) IND 12 Y CDI PR
Rosselló et al. (65) A Major depression (DISC) or CDI ≥13 Adolescents IPT (N=60); CBT (N=52) IND+ GRP 12 Y CDI PR
Schramm et al. (66) A Major depression (SCID) and HAM-D ≥16 Adult inpatients IPT+PHA (N=63); PHA (N=61) IND+ GRP 23 Y BDI, HAM-D GE
Schulberg et al. (67) O Major depression (DIS) and HAM-D ≥13 Adults IPT (N=93); PHA (N=91); UC (N=92) IND 16 Y HAM-D US
Sloane et al. (68) O Major depression (RDC) and HAM-D ≥17 Older adults IPT (N=19); PHA (N=10); PLA (N=14) IND 6 N BDI, HAM-D US
Spinelli and Endicott (69) A Major depression (SCID) and HAM-D-24 ≥12 Pregnant women IPT (N=21); parenting education (N=17) IND 10 Y BDI, EPDS, HAM-D US
Swartz et al. (70) A Major depression (SCID) and HAM-D ≥15
Mothers whose children receive psychiatric 
treatment IPT (N=26); UC (N=21) IND 9 N BDI, HAM-D US
Tang et al. (71) A BDI >19 Adolescents IPT (N=35); UC (N=38) IND 12 Y BDI TW
Van Schaik et al. (72) O Major depression (PRIME-MD) Older adults (age 55 or older) IPT (N=69); UC (N=74) IND 8 Y GDS, MADRS, PRIME-MD NL
Weissman et al. (73) O Major depression (SADS) and RTADS ≥7 Adults
IPT (N=17); IPT+PHA (N=23); on-demand telephone 
support (N=21); PHA (N=20) IND 16 N RTADS US
a A=acute treatment using an adapted manual; M=maintenance treatment; O=acute treatment using original manual.
b BDI=Beck Depression Inventory; CDI=Children’s Depression Inventory; CDRS=Cornell Dysthymia Rating Scale; CES-D=Center for Epidemio-
logic Studies Depression Scale; DIS=Diagnostic Interview Schedule; DISC=Diagnostic Interview Schedule for Children; EPDS=Edinburgh 
Postnatal Depression Scale; GDS=Geriatric Depession Scale; HADS=Hospital Anxiety and Depression Scale; HAM-D=17-item Hamilton 
Depression Rating Scale; HAM-D-24=24-item Hamilton Depression Rating Scale; K-SADS=Schedule for Affective Disorders and Schizo-
phrenia for School-Age Children; MADRS=Montgomery-Åsberg Depression Rating Scale; MCMI-III=Millon Clinical Multiaxial Inventory-III; 
PRIME-MD=Primary Care Evaluation of Mental Disorders; RDC=Research Diagnostic Criteria; RTADS=Raskin Three Area Depression Scale; 
SADS=Schedule for Affective Disorders and Schizophrenia; SCID=Structured Clinical Interview for DSM-IV Axis I Disorders.
c CBT=cognitive-behavioral therapy; COCT=coping-oriented couples therapy; IPT=interpersonal psychotherapy; PHA=pharmacotherapy; 
PLA=placebo; SUP=supportive psychotherapy; UC=usual care; WL=waiting list.
d GRP=Group treatment; IND=individual treatment; TEL=telephone treatment.
e ITT=intent to treat; N=no; Y=yes.
f AU=Australia; BR=Brazil; CA=Canada; GE=Germany; IS=Israel; IT=Italy; NL=Netherlands; NZ=New Zealand; PR=Puerto Rico; SW=Sweden; 
TW=Taiwan; UG=Uganda; UK=United Kingdom; US=United States.
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tABle 2. effect sizes in Meta-Analysis of studies comparing Interpersonal Psychotherapy With control conditions, Phar-
macotherapy, and other Psychotherapiesa
Comparison
Number of 





IPT versus control condition
All studies 16 0.63*** 0.36 to 0.90 82.96*** 2.91
Outlier removedd 15 0.52*** 0.36 to 0.68 42.84* 3.50
HAM-D only 9 0.60*** 0.39 to 0.81 40.47 3.05
BDI only 7 0.60*** 0.32 to 0.89 59.62* 3.05
Subgroup analysese
Adapted manual
No 5 0.29 0.12 to 0.47 0.00 0.004 6.17
Yes 10 0.67 0.48 to 0.85 27.52 2.75
Target group
Adults in general 3 0.37** 0.15 to 0.58 0.00 0.214 4.85
Adolescents 5 0.63*** 0.43 to 0.82 0.00 2.91
Specific target group 7 0.53** 0.19 to 0.87 68.11** 3.42
Basis of diagnosis
Diagnostic interview 12 0.57*** 0.40 to 0.73 29.74 0.424 3.18
Self-report 3 0.38 –0.04 to 0.80 67.73* 4.72
Control group
Usual care 6 0.50*** 0.28 to 0.72 32.20 0.182 3.62
Waiting list 3 0.81*** 0.42 to 1.20 59.63 2.30
Other 5 0.38** 0.14 to 0.62 0.00 4.72
Intent-to-treat analysis
Yes 10 0.57*** 0.38 to 0.76 51.56* 0.718 3.18
No 4 0.50** 0.16 to 0.84 12.97 3.62
IPT versus other psychotherapyf
All studies 13 0.04 –0.14 to 0.21 39.81 45.45
One effect size per study (highest) 10 0.01 –0.20 to 0.21 44.59 166.67
One effect size per study (lowest) 10 0.00 –0.20 to 0.19 41.11 −
HAM-D only 10 0.12 –0.07 to 0.31 19.04 14.71
BDI only 7 0.28 –0.02 to 0.57 45.46 6.41
Studies on dysthymia excluded 11 0.01 –0.18 to 0.20 42.09 166.67
Subgroup analysese
Adapted manual
Yes 7 –0.09 –0.25 to 0.07 0.00 0.098 20.00
No 6 0.25 –0.12 to 0.63 62.27* 7.14
Comparison group
CBT 9 –0.04 –0.23 to 0.16 39.72 0.113 45.45
Other psychotherapy 4 0.27 –0.06 to 0.59 4.68 6.58
Target group
Adults 8 –0.08 –0.24 to 0.08 0.00 0.116 21.74
More specific group 5 0.31 –0.15 to 0.77 69.51* 5.75
Intent-to-treat analysis
Yes 9 0.16 –0.06 to 0.38 35.74 0.106 11.11
No 3 –0.13 –0.40 to 0.15 0.00 13.51
IPT versus pharmacotherapyf
All studies 10 –0.12 –0.36 to 0.12 61.98** 14.71
Outlier removedg 9 –0.19* –0.38 to –0.01 30.95 9.43
HAM-D only 8 –0.16 –0.43 to 0.11 57.39* 11.11
BDI only 3 –0.31 –0.72 to 0.09 40.39 5.75
Studies on dysthymia excluded 7 –0.12 –0.33 to 0.09 23.78 14.71
Subgroup analysese
Medicationh
SSRI or SNRI 3 –0.39** –0.68 to –0.11 14.18 0.037 4.59
Tricyclic antidepressant 4 –0.02 –0.22 to 0.19 0.00 83.33
Intent-to-treat analysis
Yes 5 –0.15 –0.42 to 0.13 45.10 0.450 11.90
No 4 –0.28* –0.50 to –0.06 0.00 6.41
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tistically significant (p>0.05) may reflect the small number 
of studies using a waiting list control group (N=3).
IPT Compared With Other Psychotherapies
Ten studies (13 comparisons) compared posttest effects 
of IPT to another psychotherapy (Table 2; see also Figure 
S1 in the data supplement that accompanies the online 
edition of this article). On average, the 13 comparisons 
included 74 patients (37 per condition), which sufficed to 
detect an effect size of 0.25 (number needed to treat=7.14).
The overall effect size for the 13 comparisons was 0.04 
(95% CI=-0.14 to 0.21; number needed to treat=45.45) fa-
voring IPT, which was not statistically significant (p=0.40). 
Heterogeneity was low to moderate (I2=39.81%).
In these analyses we included three studies that com-
pared two psychological treatments with the same control 
group. This means that multiple comparisons from these 
three studies were included in the same analysis. The mul-
tiple comparisons, however, are not independent of one 
another, which may have resulted in artificially reduced 
heterogeneity and affected the pooled effect size. We ex-
amined such possible effects by conducting an analysis in 
which we included only one effect size per study. First, we 
cient statistical power to detect an effect size of 0.21 (num-
ber needed to treat=8.47).
Inspection of the funnel plot and Duval and Tweedie’s 
trim and fill procedure did not indicate possible publi-
cation bias: the effect size adjusted for publication bias 
exactly equaled the unadjusted effect size. None of the 
studies in this subsample specifically targeted dysthymic 
disorder.
We examined some basic moderators in subgroup 
analyses. We found no indication that type of target group 
(adults, adolescents, more specific target group), method 
of diagnosing depressive disorder (diagnostic interview 
or other), or use of intent-to-treat analyses (yes or no) 
were significantly associated with effect size, although the 
number of studies was small in several subgroups. We did 
find that the studies using the original manual produced 
significantly lower effect sizes (d=0.29; number needed to 
treat=6.17) than did studies that used an adapted manual 
(d=0.67; number needed to treat=2.75) (p<0.01). Hetero-
geneity was low and not significant in both subgroups.
Studies that used a waiting list control group yielded 
larger effect sizes than studies that employed usual care or 
other control conditions. That this difference was not sta-
tABle 2. effect sizes in Meta-Analysis of studies comparing Interpersonal Psychotherapy With control conditions, Phar-
macotherapy, and other Psychotherapiesa (continued)
Comparison
Number of 







All studies 10 0.16 –0.03 to 0.36 39.26 11.11
HAM-D only 8 0.21 –0.11 to 0.52 64.64** 8.47
BDI only 2 0.10 –0.20 to 0.41 0.00 17.86
Studies on dysthymia excluded 7 0.22 –0.03 to 0.47 44.17 8.06
Subgroup analyses
Adapted manual
Yes 5 0.23 –0.04 to 0.51 50.15 0.494 7.69
No 5 0.08 –0.25 to 0.41 40.50 21.74
Medication
SSRI 5 0.07 –0.27 to 0.41 64.96* 0.562 25.00
Tricyclic antidepressant 2 0.33 –0.11 to 0.76 0.00 5.43
Other/protocol 3 0.27 –0.00 to 0.54 0.00 6.58
Target group
Adults 5 0.07 –0.12 to 0.27 0.00 0.569 25.00
More specific group 5 0.19 –0.16 to 0.54 61.35* 9.43
Intent-to-treat analysis
Yes 6 0.12 –0.10 to 0.34 23.03 0.391 14.71
No 4 0.35 –0.12 to 0.82 63.84* 5.10
a  These data are from analysis using the random effects model. BDI=Beck Depression Inventory; HAM-D=Hamilton Depression Rating Scale; 
IPT=interpersonal psychotherapy; SNRI=serotonin/norepinephrine reuptake inhibitor; SSRI=selective serotonin reuptake inhibitor.
b  Variance between studies as a proportion of the total variance; heterogeneity tested using the I2 statistic. Low heterogeneity=25%; moder-
ate heterogeneity=50%; high heterogeneity=75%. The p values indicated in this column refer to whether the Q statistic is significant (the I2 
statistic does not include a test of significance). 
c The p values in this column indicate whether the difference between the effect sizes in the subgroups is significant.
d Bolton et al. (39).
e Subgroup analyses are conducted without outliers.
f Positive effect sizes indicate superior effects of IPT.
g Finkenzeller et al. (44).
h Two studies in which other pharmacotherapies were used (nefazodone, protocolized treatment) were excluded from these analyses.
i Positive effect sizes indicate superior effects of combination treatment.
*p<0.05. **p<0.01. ***p<0.001.
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These analyses gave no indication of publication bias; 
the unadjusted and adjusted effect sizes were identical, 
with zero imputed studies.
IPT Compared With Combination Treatment
In 10 studies the combination of IPT and pharmacother-
apy was compared with pharmacotherapy alone. These 
10 comparisons had on average 80 participants, which 
yielded enough statistical power to detect an effect size of 
0.28 (number needed to treat=6.41). The mean effect size 
indicating the difference between these two types of treat-
ment was 0.16 (95% CI=-0.03 to 0.36; number needed to 
treat=11.11) in favor of combination treatment (see Figure 
S3 in the online data supplement). This difference was 
not statistically significant, perhaps reflecting the small 
number of studies and consequent low statistical power. 
Heterogeneity was low to moderate (I2=39.26%). Remov-
ing the studies on dysthymic disorder did not yield a sig-
nificant difference either. The subgroup analyses (original 
manual versus adapted manual; adults versus more spe-
cific group; intent-to-treat analyses versus per-protocol 
analyses) identified no significant differences between 
subgroups. There were some indications for publica-
tion bias: the effect size adjusted for publication bias was 
somewhat smaller than the unadjusted effect size (d=0.07; 
95% CI=-0.13 to 0.27; number of imputed studies=3; num-
ber needed to treat=25.00).
IPT as Maintenance Treatment
We were able to compare maintenance pharmacother-
apy in patients who had recovered from a depressive dis-
order with combination treatment with IPT and pharma-
cotherapy maintenance treatment in five studies. Four of 
these presented recurrence rates. The fifth study reported 
only means and standard deviations for patients; in this 
study, the odds ratio was calculated using the procedures 
integrated in the CMA software. This resulted in an odds 
ratio of 122.77, which was considered incredible (the other 
odds ratios ranged from 1 to 3.75). We therefore did not 
use the study in these analyses. The remaining four stud-
ies generated an odds ratio of 0.37 (95% CI=0.19 to 0.73, 
p<0.01; I2=0%; number needed to treat=7.63), which 
indicates that maintenance IPT combined with phar-
macotherapy significantly reduced the recurrence rate 
compared with pharmacotherapy alone after successful 
treatment of acute depression (see Figure S4 in the online 
data supplement). Because of the small number of stud-
ies, we did not conduct additional analyses.
We were also able to compare the combination of main-
tenance IPT and pill placebo with pill placebo alone in four 
studies. The resulting odds ratio was 0.47 (95% CI=0.25 to 
0.87; I2=0%; number needed to treat=5.95), indicating that 
maintenance IPT was more protective against relapse than 
pill placebo alone. As none of the other possible compari-
sons (maintenance IPT versus control groups; mainte-
nance IPT versus pharmacotherapy) had more than two 
comparisons, we decided not to perform a meta-analysis.
included only the comparison with the largest effect size 
from the studies with multiple comparisons. Then, in an-
other analysis, we included only the smallest effect size. As 
illustrated in Table 2, the resulting effect sizes were almost 
identical to those of the overall analyses. Heterogeneity 
did not increase considerably and remained moderate to 
high in these analyses.
The mean effect size based on the HAM-D resulted 
in comparable outcomes. The effect size based on the 
BDI was somewhat larger (d=0.28; number needed to 
treat=6.41) but did not reach statistical significance. Re-
moval of the studies specifically treating dysthymic disor-
der had little effect on the overall effect size. There were no 
outlier studies.
Again, we examined possible moderators in subgroup 
analyses (Table 2). We did not find that the effect size dif-
fered significantly between studies that used an adapted 
manual and those that used the original manual; between 
studies in which IPT was compared with CBT and those 
in which IPT was compared with other psychotherapies; 
between studies treating adults in general and those tar-
geting more specific groups (e.g., adolescents, people with 
somatic illnesses); between studies using different treat-
ment formats; and between studies using intent-to-treat 
analyses and those using per-protocol analyses.
There were some indications for publication bias. After 
adjustment for publication bias, the effect size decreased 
to –0.11 (95% CI=-0.31 to 0.09; number of imputed stud-
ies=4; number needed to treat=16.13).
IPT Compared With Pharmacotherapy
Ten studies compared IPT with pharmacotherapy. 
These studies included on average 82 participants and 
had sufficient power to detect an effect size of 0.28 (num-
ber needed to treat=6.41).
A nonsignificant differential overall effect size of -0.12 
(95% CI=-0.36 to 0.12; number needed to treat=14.71) 
favored pharmacotherapy (see Figure S2 in the online 
data supplement). Heterogeneity was moderate to high 
(I2=61.98%). After removal of one possible outlier (Finken-
zeller et al. [44]), the overall effect size became signifi-
cant (d=-0.19; 95% CI=-0.38 to -0.01; number needed to 
treat=9.43, p<0.05; I2=30.95%), indicating a significant su-
perior effect of pharmacotherapy. Removal of the studies 
aimed at dysthymia resulted in comparable outcomes.
Subgroup analyses indicated that selective serotonin 
reuptake inhibitors (SSRIs) were significantly more ef-
fective than IPT (N=3; d=–0.39, p<0.01; number needed 
to treat=4.59), whereas tricyclic antidepressants were not 
(N=4; d=–0.02, p>0.1; number needed to treat=83.33), and 
the studies comparing SSRIs with IPT differed significantly 
from those examining tricyclics (p<0.05). Two of the three 
studies comparing IPT with SSRIs, however, involved pa-
tients with dysthymia. Furthermore, the number of stud-
ies in each of these subgroups was very small, so these re-
sults should be considered with caution.
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tant. Pharmacotherapy may have limited benefit in situa-
tions such as complicated grief, where IPT can be crucial. 
Medication and psychotherapies presumably work by dif-
ferent mechanisms, and they generally relieve symptoms 
in different temporal patterns. Effective psychotherapies 
such as IPT are therefore among the most important in-
struments available to clinicians.
We found that studies using the original IPT manual pro-
duced significantly lower effect sizes than studies that used 
an adapted manual. This may reflect the fact that the origi-
nal manual has been examined by several groups other 
than the inventors of IPT, whereas the adapted versions of 
the manual have been examined mainly by the researchers 
who developed them. Yet the original manual would inevi-
tably have received more use than later adaptations, and 
differences in outcomes might also derive from different 
treatment populations, therapist skills, and the adapta-
tions themselves. Nonetheless, the larger effect sizes of the 
adapted versions should be considered with caution.
This study has several limitations. First, the quality 
of the included studies was not optimal. Only nine of 38 
(24%) studies met all quality criteria. Although this pro-
portion is relatively high compared with other studies of 
psychotherapy for depression (we previously found [77] 
that only 11 of 115 [10%] controlled trials of psychother-
apy for adult depression met all quality criteria), it is still 
too low. We recommend that future research use and re-
port adequate randomization methods, correct blinding 
of outcome assessors, and intent-to-treat analyses.
Second, the number of studies in several subanalyses 
was relatively small and may have lacked statistical power 
to detect smaller effect sizes. A third limitation is that we 
found indications for publication bias in some analyses, 
although the mean effect sizes did not decrease consider-
ably after adjustment for publication bias, and none of the 
resulting effect sizes differed significantly from the unad-
justed effect sizes. This contradicts a recent meta-analysis 
of publication bias in psychotherapy for adult depression 
(78), which found no indications for publication bias of 
IPT studies. The present analysis included more studies, 
and its results can be assumed to be more up-to-date.
Despite these limitations, we found clear indications for 
the efficacy of IPT for unipolar depression. IPT is one of 
the best empirically validated psychological treatments 
for depression currently available, and its inclusion in 
treatment guidelines is justified.
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Discussion
We identified 38 randomized trials (with a total of 4,356 
patients) examining the effects of IPT. Compared with 
control groups, we found a moderate to large effect of IPT 
in the acute treatment of depression. We also found some 
indications that IPT had less efficacy than SSRI pharma-
cotherapy. However, the overall difference was small, not 
all analyses were significant, and the number of studies in 
this subsample was small.
We found indications that combination treatment with 
IPT and pharmacotherapy was somewhat more efficacious 
than pharmacotherapy alone, although this difference 
reached significance only when the HAM-D was used as an 
outcome measure. However, the effect size was also small, 
and again this subsample of studies was relatively small, 
limiting statistical power. In a larger meta-analysis of stud-
ies comparing combination treatments with psychothera-
py and pharmacotherapy and pharmacotherapy alone, we 
found that combination treatments were significantly bet-
ter than pharmacotherapy alone (74). Furthermore, com-
bination treatment may have greater efficacy for patients 
with more severe or chronic major depression (75).
We did not find that IPT had greater efficacy than other 
psychotherapies, including CBT, although the number of 
studies was too small to draw definite conclusions. IPT 
is the only type of psychotherapy for depression aside 
from CBT that has been compared with control groups, 
other psychotherapies, antidepressant medication, and 
combination treatments. Other types of psychotherapy 
are far less well examined. At present, therefore, IPT and 
CBT may be considered the best options for psychologi-
cal treatments for depression. There is no indication that 
IPT is superior to CBT, and the two seem equally effective 
overall. Whether to prescribe CBT or IPT should depend 
on patient preference and moderating factors based on 
differential therapeutics (76).
Although the number of studies examining the effects 
of maintenance IPT was small, these studies had relatively 
high methodological quality. Analysis of these studies in-
dicated that maintenance IPT combined with pharmaco-
therapy reduced the relapse rate considerably compared 
with pharmacotherapy alone. We also found that placebo 
plus IPT was more effective than placebo alone in reduc-
ing relapse rates.
Our finding that pharmacotherapy has greater efficacy 
than IPT is consistent with results from earlier meta-an-
alytic research (77); this should not come as a surprise, 
since there was considerable overlap of included studies. 
The superior effect of combination treatment over phar-
macotherapy alone also accords with earlier meta-analyt-
ic research (74). This suggests that IPT has an additional 
effect on depression beyond the effects of pharmacother-
apy, although the effect size was small.
That IPT is efficacious compared with control condi-
tions and probably augments pharmacotherapy is impor-
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